Phase II study of capecitabine and temozolomide (CAPTEM)in patients with unresectable neuroendocrien tumor

Phase II study of capecitabine and temozolomide (CAPTEM)in patients with unresectable neuroendocrien tumor - CAPTEM therapy for unresectable neuroendocrine tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024091

Enrollment

Registered

2016-09-17

Start date

2016-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroenteropancreatic neuroendocrine tumor

Interventions

Chemotherapy by Capecitabine and Temozolomide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: unresectable gastroenteropancreatic neuroeondocrine tumor (WHO 2010 Grade 1,2,3) and primary unknown NET

Exclusion criteria

Exclusion criteria: Hb < 8.0g/dl WBC <3000 Neutrocyte <1500 Plt <100000 severe liver or renal disease T-bil> 3ULN Alb <3.0g/dl AST> 5 X ULN ALT> 5 X ULN brain metastasis severe bone metastasis uncontrolable DM severe heart disease

Design outcomes

Primary

Measure	Time frame
Overall response rate	—

Secondary

Measure	Time frame
Time to treatment failure Progression-free survival Overall survival	—

Countries

Japan

Contacts

Public ContactNoritoshi Kobayashi

Yokohama City University Hospital Department of Oncology

norikoba@yokohama-cu.ac.jp045-787-2623

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026